Inquiry Basket
Loading ......
Pirlimycin hydrochloride is a veterinary antibiotic belonging to the lincosamide class of antimicrobial agents. It is primarily used to treat bacterial infections in animals, most notably mastitis in dairy cows. Mastitis is an inflammation of the mammary gland, usually caused by bacterial pathogens such as Staphylococcus aureus and Streptococcus species. This condition can lead to reduced milk production, altered milk quality, and significant economic losses in the dairy industry. By targeting the bacterial infection directly, pirlimycin helps restore udder health and maintain milk yield.
Figure 1. Pyrrolnitrin hydrochloride treats mastitis in dairy cows caused by Gram-positive bacteria by inhibiting bacterial protein synthesis.
Chemically, pirlimycin hydrochloride is a derivative of lincomycin, sharing similar structural features and antibacterial mechanisms. It works by inhibiting bacterial protein synthesis, binding specifically to the 50S ribosomal subunit of susceptible bacteria. This action prevents the translation of bacterial mRNA into proteins, effectively stopping bacterial growth. Unlike broad-spectrum antibiotics, pirlimycin is considered to have a relatively narrow spectrum, focusing on gram-positive bacteria, which are the main culprits in bovine mastitis.
The primary application of pirlimycin hydrochloride is in intramammary therapy for lactating cows. In this form, the drug is directly infused into the udder via the teat canal. This localized delivery ensures high concentrations of the antibiotic at the site of infection while minimizing systemic exposure. Such a targeted approach helps reduce the risk of antibiotic residues in milk, an important consideration in dairy production and food safety regulations.
Pirlimycin can also be used in non-lactating cows to treat chronic or persistent mastitis. Veterinary professionals often perform a clinical examination and milk culture to determine the presence of susceptible pathogens before initiating therapy. Proper diagnosis ensures effective treatment and prevents the unnecessary use of antibiotics, which can contribute to antimicrobial resistance.
Additionally, pirlimycin has been investigated for its potential use in other livestock species, though its primary and approved use remains in bovine mastitis management. It is not commonly used in humans due to species-specific pharmacokinetics and regulatory considerations.
Pirlimycin's antibacterial activity stems from its ability to interfere with bacterial protein synthesis. Specifically, it binds to the 50S ribosomal subunit within susceptible bacteria, blocking the elongation of peptide chains during translation. This inhibition effectively halts bacterial replication, allowing the animal's immune system to eliminate the infection.
Importantly, pirlimycin exhibits bacteriostatic activity, meaning it stops bacteria from multiplying rather than killing them outright. Infections in animals with healthy immune systems typically resolve as the immune system clears the inhibited bacteria. However, in cases of severe infection, supportive care or combination therapy may be necessary.
Resistance can occur when bacteria acquire genetic mutations or mobile elements that prevent pirlimycin from binding to ribosomes. This underscores the importance of judicious use and adherence to veterinary guidelines, including following correct dosages, treatment duration, and withdrawal times.
Pirlimycin hydrochloride is generally considered safe for use in cattle when administered according to label instructions. However, some side effects may occur. Local reactions at the infusion site, such as mild swelling or irritation, have been reported. Rare systemic reactions, including allergic responses, are possible but uncommon.
Proper hygiene during administration is essential to prevent secondary infections. Contaminated equipment or improper technique can introduce new pathogens into the udder, worsening mastitis. Veterinarians and farm personnel should be trained in aseptic infusion procedures to maintain both animal health and milk quality.
Pirlimycin hydrochloride is approved in many countries for veterinary use, specifically for lactating and non-lactating cows. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), establish guidelines on labeling, dosage, withdrawal periods, and safety testing.
Farmers and veterinarians must strictly follow these regulations to ensure compliance with food safety standards. Improper use, including off-label administration, can result in milk contamination and legal consequences. Monitoring programs in the dairy industry routinely test milk for antibiotic residues, emphasizing the importance of adherence to withdrawal times.
One of the main advantages of pirlimycin hydrochloride is its targeted action against gram-positive pathogens responsible for mastitis. Its intramammary administration allows high local concentrations without significant systemic exposure, reducing the risk of side effects in the animal. Furthermore, it is a well-studied and widely used drug with a proven track record in dairy herds.
However, pirlimycin has limitations. It is ineffective against gram-negative bacteria commonly associated with environmental mastitis. Additionally, like all antibiotics, its efficacy depends on correct diagnosis, adherence to dosing schedules, and prevention of resistance. It should be used as part of a comprehensive herd health management plan, including hygiene, nutrition, and regular veterinary oversight.
Pirlimycin hydrochloride is a veterinary antibiotic that plays a critical role in managing bovine mastitis. Its mechanism, targeting bacterial protein synthesis, and localized intramammary administration make it effective for treating gram-positive infections in dairy cows. Safety, proper dosage, and adherence to withdrawal periods are essential to ensure animal health and food safety. As part of a broader herd management strategy, pirlimycin hydrochloride continues to be a valuable tool in maintaining milk quality and supporting dairy production.
Pirlimycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, exerting bacteriostatic effects against gram-positive pathogens, particularly Staphylococcus aureus and Streptococcus species responsible for bovine mastitis.
The drug is delivered as an intramammary infusion into the affected udder quarter. This localized administration ensures high tissue concentrations while minimizing systemic exposure and reducing potential residues in milk.
Milk produced during and after treatment may contain antibiotic residues. Compliance with the recommended withdrawal period, as specified on the product label or by regulatory guidelines, is essential to ensure food safety and regulatory compliance.
Pirlimycin is primarily active against gram-positive bacteria, including common mastitis pathogens. It has limited efficacy against gram-negative organisms; infections caused by these pathogens may require alternative or adjunctive therapies.
Proper diagnosis, susceptibility testing, and adherence to recommended dosage and treatment duration are essential to prevent the development of antimicrobial resistance. Overuse or misuse can select for resistant bacterial strains in dairy herds.
References
| Target | Cat. No. | Product Name | Host | Application | |
| Pirlimycin | HMABPY048 | RHA™ anti-Pirlimycin monoclonal antibody, clone PIR | Mouse | ELISA, LFIA | Inquiry |
| DPABY-949 | Anti-Pirlimycin polyclonal antibody | Sheep | ELISA, Pr* | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| Pirlimycin | DAGA-043B | Pirlimycin [BSA] | BSA | LFIA | Inquiry |
| DAGA-047K | Pirlimycin [KLH] | KLH | Immunogen | Inquiry | |
| DAGA-035H | Pirlimycin [HRP] | HRP | ELISA | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| Pirlimycin | DEIANJ10 | Pirlimycin ELISA Kit | 96T | Quantitative | milk | Inquiry |
Loading ......
